Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody

Author： Camacho Luis H  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.3, 2008-03, pp. : 371-385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma

By  

Current Drug Discovery Technologies, Vol. 3, Iss. 4, 2006-12 ,pp. : 231-243

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-CTLA-4 monoclonal antibody: First report of uveitis: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1042, 2005-01 ,pp. : 6-7

Adis International

Access to resources Recommend Favorite

Improving monoclonal antibody therapies in cancer

By  

Inpharma, Vol. 1, Iss. 1238, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Current and Future Therapies Targeting the Immune System in Multiple Sclerosis

By  

Current Pharmaceutical Biotechnology, Vol. 15, Iss. 3, 2014-03 ,pp. : 276-296

Bentham Science Publishers

Access to resources Recommend Favorite

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

By Bornstein Gadi   Quéva Christophe   Tabrizi Mohammad   Abbema Anne   Chavez Carlos   Wang Ping   Foord Orit   Ahluwalia Kiran   Laing Naomi   Raja Sandhya   Wen Shenghua   Green Larry   Yang Xiaodong   Webster Carl   Stewart Ross   Blakey David  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 561-574

Springer Publishing Company

Access to resources Recommend Favorite